The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index.
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Open accessAbstract
The development and progression of human cancers are continuously and dynamically regulated by intrinsic and extrinsic factors. As a converging point of multiple oncogenic pathways, signal transducer and activator of transcription 3 (STAT3) is constitutively activated both in tumor cells and tumor-infiltrated immune cells. Activated STAT3 persistently triggers tumor progression through direct regulation of oncogenic gene expression. Apart from its oncogenic role in regulating gene expression in tumor cells, STAT3 also paves the way for human cancer growth through immunosuppression. Activated STAT3 in immune cells results in inhibition of immune mediators and promotion of immunosuppressive factors. Therefore, STAT3 modulates the interaction between tumor cells and host immunity. Accumulating evidence suggests that targeting STAT3 may enhance anti-cancer immune responses and rescue the suppressed immunologic microenvironment in tumors. Taken together, STAT3 has emerged as a promising target in cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Opposite Regulation of Myc and p21 Transcription by STAT3 Proteins
Barré, B., Avril, S., & Coqueret, O. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210422200 · Cited by 110
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Chen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“PD-1/PD-L1 axis, one such immune checkpoint, was recently validated to impede T-cell activation and thereby promotes the differentiation of CD4+ T cells into Foxp3+ regulatory T cells (94).”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Zhou, L., Ivanov, I. I., Spolski, R., Min, R., Shenderov, K., Egawa, T., Levy, D. E., Leonard, W. J., & Littman, D. R. (2007) · Nature Immunology · doi:10.1038/ni1488 · Cited by 2,141
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
The multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,853
Sakaguchi, S. (2000) · Cell · doi:10.1016/s0092-8674(00)80856-9 · Cited by 1,815
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγ
Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2007.11.016 · Cited by 1,605
STAT3 Regulates Cytokine-mediated Generation of Inflammatory Helper T Cells
Yang, X. O., Panopoulos, A. D., Nurieva, R., Chang, S. H., Wang, D., Watowich, S. S., & Dong, C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.c600321200 · Cited by 1,490
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
The transcriptional network for mesenchymal transformation of brain tumours
Carro, M. S., Lim, W. K., Alvarez, M. J., Bollo, R. J., Zhao, X., Snyder, E. Y., Sulman, E. P., Anne, S. L., Doetsch, F., Colman, H., et al. (2010) · Nature · doi:10.1038/nature08712 · Cited by 1,259
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Takeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Förster, I., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80005-9 · Cited by 1,220
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
The role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Buettner, R., Mora, L. B., & Jove, R. (2002) · PubMed · Cited by 1,185
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome
Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pasic, S., Stojkovic, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,048
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S., Niu, G., Kay, H., Mulé, J., Kerr, W. G., et al. (2005) · Nature Medicine · doi:10.1038/nm1325 · Cited by 1,031
Mechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M., Nacken, W., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 902
Role of tumor-associated macrophages in tumor progression and invasion
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9001-7 · Cited by 888
Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression
Wan, Y. Y., & Flavell, R. A. (2007) · Nature · doi:10.1038/nature05479 · Cited by 854
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
The Terminology Issue for Myeloid-Derived Suppressor Cells
Gabrilovich, D. I., Bronte, V., Chen, S.-H., Colombo, M. P., Ochoa, A., Ostrand-Rosenberg, S., & Schreiber, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3037 · Cited by 835
Tu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt-Jones, E. A., Rickman, B., Betz, K. S., Penz-Oesterreicher, M., Bjorkdahl, O., Fox, J. G., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.011 · Cited by 813
Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B.-Z., Shi, Y.-H., Xiao, Y.-S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 813
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10
Stumhofer, J. S., Silver, J. S., Laurence, A., Porrett, P. M., Harris, T. H., Turka, L. A., Ernst, M., Saris, C. J. M., O'Shea, J. J., & Hunter, C. A. (2007) · Nature Immunology · doi:10.1038/ni1537 · Cited by 775
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells
Corzo, C. A., Cotter, M. J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900092 · Cited by 763
Zorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
Alexander, W. S., & Hilton, D. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.091003.090312 · Cited by 701
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 698
Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
Knutson, K. L., & Disis, M. L. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0653-2 · Cited by 682
Lo, H.-W., Hsu, S.-C., Xia, W., Cao, X., Shih, J.-Y., Wei, Y., Abbruzzese, J. L., Hortobagyi, G. N., & Hung, M.-C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0575 · Cited by 625
Cancer Immunotherapy: A Treatment for the Masses
Blattman, J. N., & Greenberg, P. D. (2004) · Science · doi:10.1126/science.1100369 · Cited by 612
Harris, T. J., Grosso, J. F., Yen, H.-R., Xin, H., Kortylewski, M., Albesiano, E., Hipkiss, E. L., Getnet, D., Goldberg, M. V., Maris, C. H., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4313 · Cited by 583
Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice
Kujawski, M., Kortylewski, M., Lee, H., Herrmann, A., Kay, H., & Yu, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35213 · Cited by 581
Xu, Q., Briggs, J., Park, S., Niu, G., Kortylewski, M., Zhang, S., Gritsko, T., Turkson, J., Kay, H., Semenza, G. L., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208719 · Cited by 576
Gritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
Wei, D., Le, X., Zheng, L., Wang, L., Frey, J. A., Gao, A. C., Peng, Z., Huang, S., Xiong, H. Q., Abbruzzese, J. L., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206122 · Cited by 558
Xie, T.-X., Wei, D., Liu, M., Gao, A. C., Ali-Osman, F., Sawaya, R., & Huang, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207383 · Cited by 550
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway
Wei, L.-H., Kuo, M.-L., Chen, C.-A., Chou, C.-H., Lai, K.-B., Lee, C.-N., & Hsieh, C.-Y. (2003) · Oncogene · doi:10.1038/sj.onc.1206226 · Cited by 536
IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation
Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., Kamimura, D., Ueda, N., Iwakura, Y., Ishihara, K., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3844 · Cited by 519
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
Self-citationHiraoka, K., Miyamoto, M., Cho, Y., Suzuoki, M., Oshikiri, T., Nakakubo, Y., Itoh, T., Ohbuchi, T., Kondo, S., & Katoh, H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602934 · Cited by 481
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C., Pardoll, D., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.018 · Cited by 474
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464
Regulation of gene-activation pathways by PIAS proteins in the immune system
Shuai, K., & Liu, B. (2005) · Nature Reviews Immunology · doi:10.1038/nri1667 · Cited by 447
Aoki, Y., Feldman, G. M., & Tosato, G. (2003) · Blood · doi:10.1182/blood-2002-07-2130 · Cited by 438
Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., & Fu, Y.-X. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041684 · Cited by 432
Haura, E. B., Turkson, J., & Jove, R. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0195 · Cited by 430
STAT3 SIGNALING: Anticancer Strategies and Challenges
Johnston, P. A., & Grandis, J. R. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.4 · Cited by 406
Fang, W., Zhang, J., Hong, S., Zhan, J., Chen, N., Qin, T., Tang, Y., Zhang, Y., Kang, S., Zhou, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2608 · Cited by 398
Activation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393
Görgün, G. T., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 393
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R., & Tee, A. R. (2015) · Oncogene · doi:10.1038/onc.2014.164 · Cited by 391
Welte, T., Zhang, S. S. M., Wang, T., Zhang, Z., Hesslein, D. G. T., Yin, Z., Kano, A., Iwamoto, Y., Li, E., Craft, J. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237137100 · Cited by 381
Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma
Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 379
Rahaman, S. O., Harbor, P. C., Chernova, O., Barnett, G. H., Vogelbaum, M. A., & Haque, S. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206047 · Cited by 377
A Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., & Gallick, G. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208513 · Cited by 372
Strategies and Approaches of Targeting STAT3 for Cancer Treatment
Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00945 · Cited by 347
Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121606109 · Cited by 344
Vicari, A. P., Chiodoni, C., Vaure, C., Aït-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020732 · Cited by 343
Th17 Cells in Cancer: The Ultimate Identity Crisis
Bailey, S. R., Nelson, M. H., Himes, R. A., Li, Z., Mehrotra, S., & Paulos, C. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00276 · Cited by 334
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Heimberger, A. B., Abou-Ghazal, M., Reina-Ortiz, C., Yang, D. S., Sun, W., Qiao, W., Hiraoka, N., & Fuller, G. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0320 · Cited by 332
Tumor microenvironments direct the recruitment and expansion of human Th17 cells
Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., & Peng, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902813 · Cited by 324
Nefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Sen, M., Thomas, S. M., Kim, S., Yeh, J. I., Ferris, R. L., Johnson, J. T., Duvvuri, U., Lee, J., Sahu, N., Joyce, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0191 · Cited by 313
Validating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307
Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203947 · Cited by 290
Wang, R., Cherukuri, P., & Luo, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413930200 · Cited by 275
Nishihara, M., Ogura, H., Ueda, N., Tsuruoka, M., Kitabayashi, C., Tsuji, F., Aono, H., Ishihara, K., Huseby, E., Betz, U. A. K., et al. (2007) · International Immunology · doi:10.1093/intimm/dxm045 · Cited by 268
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
Zhao, D., Pan, C., Sun, J., Gilbert, C., Drews-Elger, K., Azzam, D. J., Picon-Ruiz, M., Kim, M., Ullmer, W., El-Ashry, D., et al. (2015) · Oncogene · doi:10.1038/onc.2014.257 · Cited by 267
Fujita, Y., Yagishita, S., Hagiwara, K., Yoshioka, Y., Kosaka, N., Takeshita, F., Fujiwara, T., Tsuta, K., Nokihara, H., Tamura, T., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.10 · Cited by 261
Anglesio, M. S., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P. A., House, C. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3314 · Cited by 258
Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., Haura, E., Sebti, S., Hamilton, A. D., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.261.3.3 · Cited by 255
Dechow, T. N., Pedranzini, L., Leitch, A., Leslie, K., Gerald, W. L., Linkov, I., & Bromberg, J. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404100101 · Cited by 254
S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites
Deng, J., Liu, Y., Lee, H., Herrmann, A., Zhang, W., Zhang, C., Shen, S., Priceman, S. J., Kujawski, M., Pal, S. K., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.039 · Cited by 252
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
Buchert, M., Burns, C. J., & Ernst, M. (2016) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 243
Lin, L., Hutzen, B., Zuo, M., Ball, S., Deangelis, S., Foust, E., Pandit, B., Ihnat, M. A., Shenoy, S. S., Kulp, S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2468 · Cited by 234
Larmonier, N., Marron, M., Zeng, Y., Cantrell, J., Romanoski, A., Sepassi, M., Thompson, S., Chen, X., Andreansky, S., & Katsanis, E. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0160-8 · Cited by 225
Kinjyo, I., Inoue, H., Hamano, S., Fukuyama, S., Yoshimura, T., Koga, K., Takaki, H., Himeno, K., Takaesu, G., Kobayashi, T., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052333 · Cited by 225
Panni, R. Z., Sanford, D. E., Belt, B. A., Mitchem, J. B., Worley, L. A., Goetz, B. D., Mukherjee, P., Wang-Gillam, A., Link, D. C., DeNardo, D. G., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1527-x · Cited by 214
STAT3 activation: A key factor in tumor immunoescape
Rébé, C., Végran, F., Berger, H., & Ghiringhelli, F. (2013) · JAK-STAT · doi:10.4161/jkst.23010 · Cited by 212
Perrone, G., Ruffini, P. A., Catalano, V., Spino, C., Santini, D., Muretto, P., Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.017 · Cited by 210
Role of Stat3 in suppressing anti-tumor immunity
Kortylewski, M., & Yu, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.03.010 · Cited by 196
Lin, L., Hutzen, B., Li, P.-K., Ball, S., Zuo, M., DeAngelis, S., Foust, E., Sobo, M., Friedman, L., Bhasin, D., et al. (2010) · Neoplasia · doi:10.1593/neo.91196 · Cited by 192
Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice
Zhang, L., Alizadeh, D., Van Handel, M., Kortylewski, M., Yu, H., & Badie, B. (2009) · Glia · doi:10.1002/glia.20863 · Cited by 191
Yang, C., He, L., He, P., Liu, Y., Wang, W., He, Y., Du, Y., & Gao, F. (2015) · Medical Oncology · doi:10.1007/s12032-014-0352-6 · Cited by 189
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
STAT 3 the oncogene – still eluding therapy?
Wake, M. S., & Watson, C. J. (2015) · The FEBS Journal · doi:10.1111/febs.13285 · Cited by 188
Crowley, M., Inaba, K., & Steinman, R. M. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.1.383 · Cited by 187
Marrogi, A. J., Munshi, A., Merogi, A. J., Ohadike, Y., El-Habashi, A., Marrogi, O. L., & Freeman, S. M. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971021)74:5<492::aid-ijc3>3.0.co;2-z · Cited by 183
Gomez-Rodriguez, J., Wohlfert, E. A., Handon, R., Meylan, F., Wu, J. Z., Anderson, S. M., Kirby, M. R., Belkaid, Y., & Schwartzberg, P. L. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131459 · Cited by 180
Amin, H. M., McDonnell, T. J., Ma, Y., Lin, Q., Fujio, Y., Kunisada, K., Leventaki, V., Das, P., Rassidakis, G. Z., Cutler, C., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207703 · Cited by 173
Different pathways of macrophage activation and polarization
Juhas, U., Ryba-Stanisławowska, M., Szargiej, P., & Myśliwska, J. (2015) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1150133 · Cited by 168
Chen, J., Wang, J., Lin, L., He, L., Wu, Y., Zhang, L., Yi, Z., Chen, Y., Pang, X., & Liu, M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0648 · Cited by 164
Bharadwaj, U., Li, M., Zhang, R., Chen, C., & Yao, Q. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3963 · Cited by 160
Current status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Ock, C.-Y., Kim, S., Keam, B., Kim, M., Kim, T. M., Kim, J.-H., Jeon, Y. K., Lee, J., Kwon, S. K., Hah, J. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7431 · Cited by 154
Turkson, J., Zhang, S., Mora, L. B., Burns, A. C., Sebti, S. M., & Jove, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502694200 · Cited by 153
Therapeutic Targeting of the JAK / STAT Pathway
Aittomäki, S., & Pesu, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12164 · Cited by 152
Identification of a New Series of STAT3 Inhibitors by Virtual Screening
Matsuno, K., Masuda, Y., Uehara, Y., Satō, H., Muroya, A., Takahashi, O., Yokotagawa, T., Furuya, T., Okawara, T., Otsuka, M., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000273 · Cited by 150
Zhang, X., Sun, Y., Pireddu, R., Yang, H., Urlam, M. K., Lawrence, H. R., Guida, W. C., Lawrence, N. J., & Sebti, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3175 · Cited by 149
Timofeeva, O. A., Tarasova, N. I., Zhang, X., Chasovskikh, S., Cheema, A. K., Wang, H., Brown, M. L., & Dritschilo, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211805110 · Cited by 146
Takezawa, K., Okamoto, I., Nishio, K., Janne, P. A., & Nakagawa, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2798 · Cited by 146
STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells
Hoentjen, F., Sartor, R. B., Ozaki, M., & Jobin, C. (2004) · Blood · doi:10.1182/blood-2004-04-1309 · Cited by 142
Andaloussi, A. E., & Lesniak, M. S. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9314-y · Cited by 142
Lee, J. H., Chiang, S. Y., Nam, D., Chung, W., Lee, J., Na, Y.-S., Sethi, G., & Ahn, K. S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.008 · Cited by 141
Herrmann, A., Kortylewski, M., Kujawski, M., Zhang, C., Reckamp, K. L., Armstrong, B., Wang, L. Q., Kowolik, C. M., Deng, J., Figlin, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0736 · Cited by 138
Priceman, S. J., Kujawski, M., Shen, S., Cherryholmes, G. A., Lee, H., Zhang, C., Kruper, L. L., Mortimer, J. E., Jove, R., Riggs, A. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311557110 · Cited by 134
Nagel‐Wolfrum, K., Buerger, C., Wittig, I., Butz, K., Hoppe‐Seyler, F., & Groner, B. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.170.2.3 · Cited by 133
Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131
Huang, W., Dong, Z., Wang, F., Peng, H., Liu, J., & Zhang, J. (2014) · ACS Chemical Biology · doi:10.1021/cb500071v · Cited by 128
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122
Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003082 · Cited by 122
Self-citationHuang, W., Dong, Z., Chen, Y., Wang, F., Wang, C. J., Peng, H., He, Y., Hangoc, G., Pollok, K. E., Sandusky, G. E., et al. (2015) · Oncogene · doi:10.1038/onc.2015.215 · Cited by 116
Herbeuval, J., Lelièvre, E., Lambert, C., Dy, M., & Genin, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4630 · Cited by 115
AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
Plimack, E. R., LoRusso, P. M., Mccoon, P. E., Tang, W., Krebs, A. D., Curt, G. A., & Eckhardt, S. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0198 · Cited by 115
Cheng, Y., Holloway, M. P., Nguyen, K., McCauley, D., Landesman, Y., Kauffman, M. G., Shacham, S., & Altura, R. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0416 · Cited by 110
Komohara, Y. (2011) · Oncology Reports · doi:10.3892/or.2011.1454 · Cited by 108
Essential role of IL-10/STAT3 in chronic stress-induced immune suppression
Hu, D., Wan, L., Chen, M., Caudle, Y., LeSage, G., Li, Q., & Yin, D. (2013) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2013.10.016 · Cited by 107
Nishikawa, H., Kato, T., Tawara, I., Ikeda, H., Kuribayashi, K., Allen, P. M., Schreiber, R. D., Old, L. J., & Shiku, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4433 · Cited by 105
Li, S. Q., Cheuk, A., Shern, J. F., Song, Y., Hurd, L., Liao, H., Wei, J. S., & Khan, J. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076551 · Cited by 102
Song, L., Smith, M. A., Doshi, P. D., Sasser, K., Fulp, W. J., Altiok, S., & Haura, E. B. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000193 · Cited by 101
STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis
Yue, C., Shen, S., Deng, J., Priceman, S. J., Li, W., Huang, A., & Yu, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0014 · Cited by 100
STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity
Ning, Z.-Q., Li, J., McGuinness, M., & Arceci, R. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204590 · Cited by 94
Fuh, B., Sobo, M., Cen, L., Josiah, D. T., Hutzen, B. J., Cisek, K. K., Bhasin, D. K., Regan, N., Lin, L., Chan, C., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604793 · Cited by 94
Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3
Kawakami, Y., Inagaki, N., Salek‐Ardakani, S., Kitaura, J., Tanaka, H., Nagao, K., Kawakami, Y., Xiao, W., Nagai, H., Croft, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509784103 · Cited by 92
Kong, L.-Y., Wei, J., Sharma, A. K., Barr, J., Abou-Ghazal, M. K., Fokt, I., Weinberg, J. S., Rao, G., Grimm, E. A., Priebe, W., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0618-y · Cited by 89
Hung, W., & Elliott, B. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010715200 · Cited by 88
Santarelli, R., Gonnella, R., Giovenale, G. D., Cuomo, L., Capobianchi, A., Granato, M., Gentile, G., Faggioni, A., & Cirone, M. (2014) · Scientific Reports · doi:10.1038/srep04241 · Cited by 79
Gene-based strategies for the immunotherapy of cancer
Tüting, T., Storkus, W. J., & Lotze, M. T. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050133 · Cited by 79
Expression of Tumor-Associated Macrophage in Progression of Human Glioma
Ding, P., Wang, W., Wang, J., Yang, Z., & Xue, L. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0105-3 · Cited by 78
Zang, C., Liu, X., Li, B., He, Y., Jing, S., He, Y., Wu, W., Zhang, B., Ma, S., Dai, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14495 · Cited by 77
Full Oncogenic Activities of v-Src Are Mediated by Multiple Signaling Pathways
Odajima, J., Matsumura, I., Sonoyama, J., Daino, H., Kawasaki, A., Tanaka, H., Inohara, N., Kitamura, T., Downward, J., Nakajima, K., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001606200 · Cited by 74
Dercamp, C., Chemin, K., Caux, C., Trinchieri, G., & Vicari, A. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1319 · Cited by 70
A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells
Wojcik, E. J., Sharifpoor, S., Miller, N., Wright, T. G., Watering, R., Tremblay, E. A., Swan, K., Mueller, C. R., & Elliott, B. E. (2005) · Oncogene · doi:10.1038/sj.onc.1209306 · Cited by 63
Eichten, A., Su, J., Adler, A. P., Zhang, L., Ioffe, E., Parveen, A. A., Yancopoulos, G. D., Rudge, J. S., Lowy, I., Lin, H. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1443 · Cited by 63
An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer
Sun, Z., Yao, Z., Liu, S., Tang, H., & Xiong, Y. (2006) · Immunobiology · doi:10.1016/j.imbio.2005.11.004 · Cited by 59
Kathiria, A. S., Neumann, W. L., Rhees, J., Hotchkiss, E. C., Cheng, Y., Genta, R. M., Meltzer, S. J., Souza, R. F., & Theiss, A. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0603 · Cited by 59
Schaper, F., Siewert, E., Gómez-Lechón, M. J., Gatsios, P., Sachs, M., Birchmeier, W., Heinrich, P. C., & Castell, J. V. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00167-1 · Cited by 53
Inhibition of p-STAT3 Enhances IFN-α Efficacy against Metastatic Melanoma in a Murine Model
Kong, L.-Y., Gelbard, A. H., Wei, J., Reina-Ortiz, C., Wang, Y., Yang, E. C. C., Hailemichael, Y., Fokt, I., Jayakumar, A., Qiao, W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0279 · Cited by 53
Self-citationWang, Y., Wang, S., Wu, Y., Ren, Y., Li, Z., Yao, X., Zhang, C., Ye, N., Jing, C., Dong, J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0606 · Cited by 53
Self-citationCHOI, J., Ahn, M., PARK, C., Han, H., Kwon, S.-J., LEE, Y., & Kim, I. S. (2006) · Apmis · doi:10.1111/j.1600-0463.2006.apm_401.x · Cited by 49
Burdelya, L. G., Catlett-Falcone, R., Levitzki, A., Cheng, F., Mora, L. B., Sotomayor, E. M., Coppola, D., Sun, J., Sebti, S. M., Dalton, W. S., et al. (2002) · PubMed · Cited by 49
Resetca, D., Haftchenary, S., Gunning, P. T., & Wilson, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595454 · Cited by 47
Regis, G., Icardi, L., Conti, L., Chiarle, R., Piva, R., Giovarelli, M., Poli, V, & Novelli, F. (2009) · Leukemia · doi:10.1038/leu.2009.139 · Cited by 47
Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma
Mochizuki, D., Adams, A., Warner, K. A., Zhang, Z., Pearson, A. T., Misawa, K., McLean, S. A., Wolf, G. T., & Nor, J. E. (2015) · Oncotarget · doi:10.18632/oncotarget.4477 · Cited by 45
Importance of CD4+ Helper T-cells in Antitumor Immunity
Shiku, H. (2003) · International Journal of Hematology · doi:10.1007/bf02986610 · Cited by 44
Li, C., Zhang, F., Lin, M., & Liu, J. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000041594.36418.f6 · Cited by 40
Appelmann, I., Rillahan, C. D., de Stanchina, E., Carbonetti, G., Chen, C., Lowe, S. W., & Sherr, C. J. (2014) · Blood · doi:10.1182/blood-2014-09-601062 · Cited by 40
Lesinski, G. B., Trefry, J. C., Brasdovich, M., Kondadasula, S. V., Sackey, K., Zimmerer, J. M., Chaudhury, A. R., Yu, L., Zhang, X., Crespin, T. R., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3092 · Cited by 39
Liu, J., Xu, X., Feng, X., Zhang, B., & Wang, J. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-80 · Cited by 37
Verstovšek, S., Hoffman, R., Mascarenhas, J. O., Soria, J., Bahleda, R., Mccoon, P. E., Tang, W., Cortes, J. E., Kantarjian, H. M., & Ribrag, V. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.11.018 · Cited by 34
Miklóssy, G., Youn, U. J., Yue, P., Zhang, M., Chen, C.-H., Hilliard, T. S., Paladino, D., Li, Y., Choi, J. C.-B., Sarkaria, J. N., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00686 · Cited by 29
The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells
Zhang, B., Lu, Z., Hou, Y., Hu, J., & Wang, C. (2014) · Tumor Biology · doi:10.1007/s13277-014-1704-8 · Cited by 23
Ma, J., Cui, B., Ding, X., Wei, J., & Cui, L. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1635-9 · Cited by 19
Maenhout, S. K., Four, S. D., Corthals, J., Neyns, B., Thielemans, K., & Aerts, J. L. (2014) · Oncotarget · doi:10.18632/oncotarget.2254 · Cited by 18
Cited by
Xiong, J., He, J., Zhu, J., Pan, J., Liao, W., Ye, H., Wang, H., Song, Y., Du, Y., Cui, B., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.02.033 · Cited by 804
The role of IL-6/JAK2/STAT3 signaling pathway in cancers
Huang, B., Lang, X., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023177 · Cited by 479
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Chemotherapy: a double-edged sword in cancer treatment
Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 397
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 396
Metadata
- Authors
- Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 415
- Pages
- 117-128
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2773508782
- Cited by
- 340
- References
- 202
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.